Scott Balsitis | Senior Director, Hepatitis B Cure Research,
Gilead Sciences
Dr. Balsitis is Head of HBV Cure Research at Gilead Sciences. He has over 20 years of experience in the pathogenesis and immunology of chronic viral infections, and has spent the last 10 years researching and developing novel agents designed to deliver functional cures for chronic hepatitis B.
Appearances:
Day 2 - November 29 @ 11:50
Hepatitis therapeutics and vaccines development
Day 2 - November 29 @ 16:30
Panel: Toward a Hepatitis B-Free Future: Perspectives on Achieving a Functional Cure
- li>
- How do you define a functional / partial cure – how should we use these terms and what are their limitations?
- Which technologies/ modalities are we using to achieve a functional cure? What are the limits of different approaches? Can they be combined for more therapeutic benefit? (Antivirals, Antibodies, Vaccines, siRNA
- Components to an effective cure strategy:
o Use of viral replication inhibitors
o Reducing viral surface antigen load – do we still have room to further reduce load?
o Activation of antiviral immune response
- Challenges in balancing side-effects and therapeutic efficacy
How do we manage / avoid resistance
last published: 02/Jan/24 12:15 GMT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events